We address questions of broad importance in cancer therapy and tumor biology: how and when does resistance to targeted therapy arise? How does genome evolution across distinct metastases affect the course of disease? How do variants in the non-coding genome affect therapy response? We are particularly focused on understanding how to detect and overcome resistance to PARP inhibitor and androgen-targeted therapy in advanced prostate cancer, a disease that is uniformly fatal.
Our lab is part of the Department of Urology and the Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco.
Circos plots of prostate tumor genomes with BRCA2,
CDK12, and TP53 inactivation